Pharsight

Recarbrio patents expiration

Can you believe RECARBRIO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8487093 MSD MERCK CO β-lactamase inhibitors
Nov, 2029

(5 years from now)

Recarbrio is owned by Msd Merck Co.

Recarbrio contains Cilastatin Sodium; Imipenem; Relebactam.

Recarbrio has a total of 1 drug patent out of which 0 drug patents have expired.

Recarbrio was authorised for market use on 16 July, 2019.

Recarbrio is available in powder;intravenous dosage forms.

Recarbrio can be used as treatment of complicated urinary tract infections, including pyelonephritis (cuti).

Drug patent challenges can be filed against Recarbrio from 16 July, 2028.

The generics of Recarbrio are possible to be released after 19 November, 2029.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 16, 2024
Generating Antibiotic Incentives Now(GAIN) Jul 16, 2029

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using CILASTATIN SODIUM; IMIPENEM; RELEBACTAM ingredient

NCE-1 date: 16 July, 2028

Market Authorisation Date: 16 July, 2019

Treatment: Treatment of complicated urinary tract infections, including pyelonephritis (cuti)

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

RECARBRIO family patents

Family Patents